Skip to main content
HR 7037 116th Congress House

To provide for quality assurance of COVID-19 reimbursements and reporting.

Introduced: May 27, 2020 See on congress.gov
Health Cardiovascular and respiratory healthDrug safety, medical device, and laboratory regulationEmergency medical services and trauma careFraud offenses and financial crimes
More subjectsShow fewer subjects
Health care costs and insuranceHealth care coverage and accessHealth information and medical recordsHealth programs administration and fundingInfectious and parasitic diseasesMedical tests and diagnostic methods
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 27, 2020
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 27, 2020
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action May 27, 2020

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

 Plain-English summary Congressional Research Service

This bill (1) establishes documentation requirements for testing, treatment, and reporting related to COVID-19 (i.e., coronavirus disease 2019); and (2) makes it unlawful to knowingly report a false diagnosis of COVID-19. To receive a federal reimbursement for the cost of a COVID-19 diagnostic test or treatment, the request for reimbursement must document that the administered COVID-19 test has been approved, cleared, or authorized by the Food and Drug Administration.

Further, the Centers for Disease Control and Prevention must exclude from its official COVID-19 case and death counts any person who tested positive and requested federal reimbursement without the required documentation.

Additionally, any person who knowingly reports a false diagnosis of COVID-19 is subject to criminal fines and imprisonment for not more than 10 years.

 Related & companion bills 1
  • HR 311 Reintroduced Bill To provide for quality assurance of COVID-19 reimbursements and reporting.
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 7037: To provide for quality assurance of COVID-19 reimbursements and reporting.. 116th Congress. Open America. https://openamerica.io/bill/116-HR-7037/
MLA
"H.R. 7037: To provide for quality assurance of COVID-19 reimbursements and reporting.." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-7037/.
Bluebook (legal)
H.R. 7037, 116th Cong. (2026), https://openamerica.io/bill/116-HR-7037/.
Markdown link
[H.R. 7037: To provide for quality assurance of COVID-19 reimbursements and reporting.](https://openamerica.io/bill/116-HR-7037/)
Report a problem